This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00255723
First received: November 18, 2005
Last updated: December 22, 2015
Last verified: December 2015
Results First Received: December 22, 2015  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Lymphoma
Interventions: Drug: carboplatin
Drug: etoposide
Drug: ifosfamide

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Arm A Standard dose ICE x 1 cycle, followed by augmented ICE x 1 cycle (0-1 risk factors)
Arm B Augmented ICE x 2 cycles (2 risk factors)

Participant Flow:   Overall Study
    Arm A   Arm B
STARTED   56   41 
COMPLETED   54   39 
NOT COMPLETED   2   2 
Adverse Event                1                1 
Death                0                1 
Response Data Not Available                1                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Arm A Standard dose ICE x 1 cycle, followed by augmented ICE x 1 cycle (0-1 risk factors)
Arm B Augmented ICE x 2 cycles (2 risk factors)
Total Total of all reporting groups

Baseline Measures
   Arm A   Arm B   Total 
Overall Participants Analyzed 
[Units: Participants]
 56   41   97 
Age 
[Units: Participants]
     
<=18 years   1   0   1 
Between 18 and 65 years   55   38   93 
>=65 years   0   3   3 
Gender 
[Units: Participants]
     
Female   35   21   56 
Male   21   20   41 


  Outcome Measures

1.  Primary:   Overall Objective Response   [ Time Frame: 3 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Craig Moskowitz
Organization: Memorial Sloan Kettering Cancer Center
phone: 212-639-7992
e-mail: moskowic@mskcc.org


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00255723     History of Changes
Other Study ID Numbers: 04-047
MSKCC-04047
Study First Received: November 18, 2005
Results First Received: December 22, 2015
Last Updated: December 22, 2015